Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective Study.

Int J Dermatol · 2026 · PMC12783438 · PMID 40836376

Europe PMC DOI

hedged sentences

0.0970

closest p · 1.9× alpha

0.0970

boldest claim

The sentences

a nonsignificant trendp = 0.097so close (0.05 < p ≤ 0.1)

Among tested variables (sex, age, history of conjunctivitis, and the time interval [in weeks] between initiation of biologic drugs and onset of conjunctivitis, prior conjunctivitis, and time to symptom onset), male sex showed a nonsignificant trend toward more severe conjunctivitis ( p = 0.097).

also in 5,406 other papers

showed a trendno p-value reported

While the dupilumab group showed a trend toward more frequent severe conjunctivitis and ophthalmologic referrals, none of these differences reached statistical significance.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.